SOBUZOXANE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H34N4O10
Molecular Weight	514.5262
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)COC(=O)OCN1C(=O)CN(CCN2CC(=O)N(COC(=O)OCC(C)C)C(=O)C2)CC1=O

InChI

InChIKey=OCOKWVBYZHBHLU-UHFFFAOYSA-N

InChI=1S/C22H34N4O10/c1-15(2)11-33-21(31)35-13-25-17(27)7-23(8-18(25)28)5-6-24-9-19(29)26(20(30)10-24)14-36-22(32)34-12-16(3)4/h15-16H,5-14H2,1-4H3

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9685054
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/10632373 http://www.ncbi.nlm.nih.gov/pubmed/8384067 http://www.anticancer-drug.net/plant_alkaloids/sobuzoxane.htm

Sobuzoxane (MST-16), a dioxopiperazine, chelates metal cations and reduces the generation of free radicals due to metal-anthracycline complexes. It interacts with topoisomerase II and blocks the formation of topoisomerase II-DNA complex. Sobuzoxane effectively blocks cell proliferation and blocks cells in G2/M phase in selected human tumor cell lines. It protects cardiomyocytes from the cardiotoxicity induced by prolonged doxorubicin treatment. It’s indicated for treatment malignant lymphoma, is also used in adult T-cell leukemia.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA topoisomerase II 66 Target ID: CHEMBL2094255 Sources: http://www.ncbi.nlm.nih.gov/pubmed/1654204	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Malignant lymphoma 10 Sources: http://www.anticancer-drug.net/plant_alkaloids/sobuzoxane.htm	Primary		Approved 8429	Perazorin Approved Use malignant lymphoma, is also used in adult T-cell leukemia.
T-cell leukemia 1 Sources: http://www.anticancer-drug.net/plant_alkaloids/sobuzoxane.htm	Primary		Approved 8429	Perazorin Approved Use malignant lymphoma, is also used in adult T-cell leukemia.

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

1600 mg/m2 a day for 5-7 days at intervals of 2-3 weeks

Route of Administration: Oral

In Vitro Use Guide

IC50 against HeLa cell line of MST-16 (SOBUZOXANE) was 26.4 uM. MST-16 affecting chromosome segregation and leading also to cell G2/ M phase arrests, which finally reduces cell division rates

Name

Type

Language

SOBUZOXANE

Official Name

English

SOBUZOXANE [MART.]

Common Name

English

sobuzoxane [INN]

Common Name

English

SOBUZOXANE [MI]

Common Name

English

SOBUZOXANE [JAN]

Common Name

English

Sobuzoxane [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1968